Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

PSMA-617

Alternative Names: psma-617, psma 617, psma617
Latest Update: 2025-04-23
Latest Update Note: Clinical Trial Update

Product Description

gallium-68-(68 Ga)-prostate-specific membrane antigen (Sourced from: gallium-68-(68 Ga)-prostate-specific membrane antigen)

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PSMA-617

Countries in Clinic: Australia, Austria, Belgium, China, Czech Republic, Denmark, France, Germany, Italy, Netherlands, Poland, Singapore, Slovakia, South Africa, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: Prostate Cancer

Phase 2: Adenocarcinoma|Hepatocellular Carcinoma|Liver Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PRELUDE

P2

Recruiting

Adenocarcinoma|Prostate Cancer

2029-03-01

PSMAcTION

P3

Recruiting

Prostate Cancer

2028-05-09

AcTFirst

P3

Not yet recruiting

Prostate Cancer

2027-12-31

RADIODOSE

P1

Recruiting

Prostate Cancer

2027-12-27

Recent News Events

Date

Type

Title

04/01/2025

News Article

 ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176

03/27/2025

News Article

 Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

03/20/2025

News Article

 Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor

03/07/2025

News Article

 Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™

05/11/2024

PubMed

 Hematological and renal toxicity in mice after three cycles of high activity [(177)Lu]Lu-PSMA-617 with or without human alpha(1)-microglobulin.

05/10/2024

PubMed

 A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer.

04/25/2024

PubMed

 Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions